Bit Digital Inc vs Novavax Inc — how do they compare? Bit Digital Inc trades at $1.46 (market cap $471.05M), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 2.8× Bit Digital Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BTBT | NVAX | |
|---|---|---|
Market Cap | $471.05M | $1.31B |
Sector | Technology | Health |
52-Week High | $4.22 | $11.19 |
52-Week Low | $1.23 | $6.22 |
Enterprise Value | $760.36M | $889.30M |
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.44, up 10.77% over 24 hours, but faces a bearish technical outlook with 14 sell signals against 2 buy signals. The company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45%, though it maintains a gross profit margin of 55.57%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in subsequent quarters. The stock is closely watched by investors ahead of its Q2 2026 earnings release on August 13, 2026.
The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing inflows. Analyst consensus is bullish with a 100% buy rating from two firms and a $5.12 average price target, suggesting significant upside potential if the company can improve profitability. Key risks include execution challenges, competitive pressures, and reliance on external financing to sustain operations.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Latest headlines on both assets
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →